Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05947409
Other study ID # SMARTO ONE-202305-2
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 15, 2023
Est. completion date December 31, 2024

Study information

Verified date August 2023
Source Beijing University of Chinese Medicine
Contact Li Liu
Phone 16619733315
Email lily0496@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. Explore the effects of natural plant flavonoids on the positive intervention mechanism of neurotransmitter transmission physiological indicators changes (EEG) in the brain of the study subjects; 2. Investigate the effects of natural plant flavonoids in positively intervening clinical symptoms of the study subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 31, 2024
Est. primary completion date June 15, 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age: 25-70 years 2. Patients complaining of sleep disorders, mood disorders (unstable mood, irritability, depression and anxiety) and cognitive decline (people with memory, decreased reaction time, BPSD symptoms) within one month 3. Montreal Cognitive Assessment Scale (MOCA) score =26; if MOCA score is not satisfied, then Pittsburgh Sleep Quality Index (PSQI) score >10 and Hamilton Anxiety Scale (HAMA) score >14 or Hamilton Depression Scale (HAMD) score =8 are required 4. Patients who can understand and communicate in language, and complete aphasia patients are not included; 5. Patients who agree to participate in this clinical observation and sign the informed consent form. Exclusion Criteria: 1. Patients with severe organ diseases such as heart, kidney, and liver failure, chronic lung diseases such as COPD, and severe diabetes; 2. Patients with severe uncontrolled hypertension; 3. Patients who have taken antipsychotic drugs within the past two weeks; 4. Patients with the core features of Lewy body dementia or significant behavioral variant frontotemporal dementia; 5. Patients with various malignant tumors; 6. Patients with progressive stroke, transient ischemic attack, cerebral hemorrhage after cerebral infarction, and cerebral arteritis; 7. Patients with brain tumors, brain trauma, cerebral parasitic diseases, and other conditions; 8. Pregnant or lactating women; 9. Patients allergic to the known ingredients used in this trial; 10. Patients with active ulcers or bleeding tendencies; 11. Patients with neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis, and Pick's disease; 12. Other patients who are deemed unsuitable to participate in this trial by the investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SMARTO ONE
The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mei Han

Outcome

Type Measure Description Time frame Safety issue
Primary Montreal Cognitive Assessment (MoCA) This outcome measure assesses cognitive ability and memory, with evaluation based on a scoring system.The total score ranges from 0 to 30 points, with scores lower than 26 indicating the presence of cognitive impairment. The lower the score, the more severe the disease. 4 weeks
Primary Pittsburgh Sleep Quality Index (PSQI) The evaluation criteria for this outcome measure are as follows: 0-5 points indicate very good sleep quality; 6-10 points indicate average sleep quality; 11-15 points indicate poor sleep quality; 16-21 points indicate very poor sleep quality. 4 weeks
Primary Hamilton Anxiety Rating Scale (HAMA) The evaluation criteria for this outcome measure are as follows: 0-6 points indicate no anxiety symptoms; 7-14 points indicate possible anxiety; 15-21 points indicate definite anxiety; 22-29 points indicate significant anxiety; and scores exceeding 29 points suggest severe anxiety. 4 weeks
Primary Hamilton Depression Scale(HAMD) The evaluation criteria for this outcome measure are as follows:a score of less than 8 is normal, a score of 8-20 may indicate depression, a score of 21-35 may indicate depression, and a score of more than 35 may not indicate severe depression 4 weeks
Secondary Numerry of participating with adverse events This is a safety outcome. baseline, 4 weeks
Secondary Adverse event occurrence rate This is a safety outcome. baseline, 4 weeks
Secondary Abnormality rate of routine blood tests This is a safety outcome. Included in the outcome indicators are red blood cell count (WBC), haemoglobin concentration (Hb), white blood cell count (WBC), neutrophil count (Neut), lymphocyte count (Lymph), monocyte count (Mono), eosinophil count (Eos), basophil count (Baso) and platelet count (PLT). The abnormal blood count rate was obtained by dividing the number of people with abnormal blood counts by the total number of people with abnormal blood counts. baseline, 4 weeks
Secondary Liver function-Alanine aminotransferase#ALT# This is a safety outcome. baseline, 4 weeks
Secondary Liver function-Aspartate aminotransferase (AST) This is a safety outcome. baseline, 4 weeks
Secondary Liver function-Total Protein(TP) This is a safety outcome. baseline, 4 weeks
Secondary Electrocardiogram This is a safety outcome.This outcome measure primarily observes ST segment changes to evaluate the presence or improvement of myocardial ischemia. baseline, 4 weeks
Secondary Body temperature This is a safety outcome. baseline, 4 weeks
Secondary Heart rate This is a safety outcome. baseline, 4 weeks
Secondary Number of breaths in 1 min This is a safety outcome. baseline, 4 weeks
Secondary Blood pressure-Diastolic blood pressure(mmHg) This is a safety outcome. baseline, 4 weeks
Secondary Blood pressure-Systolic blood pressure(mmHg) This is a safety outcome. baseline, 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT05788133 - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training. N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Recruiting NCT04265482 - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting NCT02222779 - Quantification of Transition Metals N/A
Recruiting NCT01291550 - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples N/A
Completed NCT01450891 - Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease N/A
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Recruiting NCT06148233 - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Completed NCT06251830 - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Completed NCT03353207 - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed NCT05095870 - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting NCT05784090 - Correlation Between Melatonin Levels in Different Biological Fluids
Completed NCT02108769 - Yogic Breathing Changes Salivary Components N/A
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT04820881 - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
Recruiting NCT05235802 - Long-term Follow-up in Severe Traumatic Brain Injury